Contingency Management for Smoking Cessation Among Veterans With Psychotic Disorders
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00508560 |
Recruitment Status
:
Terminated
(Stopped due to low recruitment.)
First Posted
: July 30, 2007
Last Update Posted
: June 26, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Nicotine Dependence Psychotic Disorders | Behavioral: Contingency Management Behavioral: Reward | Not Applicable |
Schizophrenia and other psychotic disorders are highly prevalent in the VA population and are associated with high rates of smoking. Although smoking cessations approaches that work for non-schizophrenic patients such as behavioral counseling and medications appear to be efficacious for schizophrenic smokers, a major obstacle in providing adequate treatment is poor attendance at treatment sessions. Contingency management has been shown to shape treatment behavior in non-schizophrenic smokers and to shape other behaviors such as cocaine use and exercise in schizophrenics.
The intention of this project is to examine the use of contingent incentives to increase attendance at smoking cessation treatment sessions by smokers with schizophrenia and other psychoses and to compare two different approaches to providing contingent incentives in this context. Subjects in the experimental condition draw from a fishbowl to obtain tokens when they attend a smoking cessation treatment session. The number of draws will be based upon attendance at consecutive sessions. Subjects in the experimental condition receive a set reward that will not change regardless of attendance at consecutive sessions. We hypothesize that the participants in the experimental condition will attend more smoking cessation group therapy sessions than those in the control condition because they will have the possibility, although not the likelihood, to obtain contingent reinforcement of greater value.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 23 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Contingency Management for Smoking Cessation Among Veterans With Schizophrenia or Other Psychoses |
Study Start Date : | July 2007 |
Actual Primary Completion Date : | December 2012 |
Actual Study Completion Date : | December 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm 1
Experimental
|
Behavioral: Contingency Management
Participants draw from a fishbowl to obtain tokens when they attend a smoking cessation treatment session. The number of draws will be based upon attendance at consecutive sessions. Tokens include messages of encouragement ("Good job!") or VA canteen vouchers of varying monetary value.
|
Active Comparator: Arm 2
Active Comparator
|
Behavioral: Reward
Participants receive set reward (VA canteen voucher) for each week of smoking cessation treatment they attend. The value of the reward will not change regardless of attendance at consecutive sessions.
|
- Number of treatment sessions attended [ Time Frame: 11 weeks ]
- Reduction in cigarettes per day [ Time Frame: 3 and 6 months ]
- 7- and 30-day point prevalence abstinence [ Time Frame: 3 and 6 months ]
- Continuous abstinence from quit date [ Time Frame: 3 and 6 months ]
- Days to relapse from quit date [ Time Frame: Up to 6 months ]
- Change in BPRS scores [ Time Frame: 3 and 6 months ]
- Change in PHQ-9 scores [ Time Frame: 3 and 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All subjects must be diagnosed with schizophrenia or any other psychotic disorder, bipolar disorder with psychotic features, or major depression with psychotic features according to the electronic medical record.
- Current nicotine use, defined as smoking 5 or more cigarettes/day for at least 16 of the past 30 days prior to study screening.
- Prospective subjects must indicate willingness to attend smoking cessation group therapy.
Exclusion Criteria:
- Imminent risk for suicide or violence.
- Severe psychiatric symptoms or psychosocial instability likely to prevent participation in the study protocol (i.e., attendance at scheduled sessions, ability to read study materials, and/or ability to comprehend interventions).
- Clinically apparent, gross cognitive impairment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00508560
United States, Washington | |
VA Puget Sound Health Care System | |
Seattle, Washington, United States, 98109 |
Principal Investigator: | Andrew J. Saxon, MD | VA Puget Sound Health Care System |
Responsible Party: | VA Office of Research and Development |
ClinicalTrials.gov Identifier: | NCT00508560 History of Changes |
Other Study ID Numbers: |
SUD-Q |
First Posted: | July 30, 2007 Key Record Dates |
Last Update Posted: | June 26, 2015 |
Last Verified: | June 2015 |
Keywords provided by VA Office of Research and Development:
Contingency management Smoking cessation Psychotic disorders Veterans |
Additional relevant MeSH terms:
Mental Disorders Psychotic Disorders Tobacco Use Disorder |
Schizophrenia Spectrum and Other Psychotic Disorders Substance-Related Disorders Chemically-Induced Disorders |